ClinicalTrials.gg
CompletedNCT03349710Updated Aug 9, 2021Results posted

Nivolumab or Nivolumab Plus Cisplatin, in Combination With Radiotherapy in Patients With Cisplatin-ineligible or Eligible Locally Advanced Squamous Cell Head and Neck Cancer

A Phase 3 interventional study of Nivolumab and Cetuximab in Squamous Cell Carcinoma of the Head and Neck, sponsored by Bristol-Myers Squibb. Completed at 55 sites in 10 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-08-09.

Sponsored by Bristol-Myers Squibb · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
74
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 46 studies testing nivolumab in Squamous Cell Carcinoma of Head and Neck — 11 open to participants now, 15 under way, 2 of them phase 3. Nivolumab · Squamous Cell Carcinoma of Head and Neck.

Enrollment
13th of 46
74 · median 44
Started
2017
with 7 others
Phase 3
6 of 46
none open now
Registered
9th of 46
by date
Lead sponsor
2 of 46
Bristol-Myers Squibb

Among the 46 studies testing nivolumab in Squamous Cell Carcinoma of Head and Neck, this one is the 13th largest by enrollment, is one of 8 that started in 2017, is one of 6 in phase 3, and was the 9th registered.

Squamous Cell Carcinoma of Head and Neck

2,019 studies on the registry are indexed under Squamous Cell Carcinoma of Head and Neck; 573 are open to participants now.

Browse Squamous Cell Carcinoma of Head and Neck studies →

Open to participants now

11 of the 46 studies testing nivolumab in Squamous Cell Carcinoma of Head and Neck are open now, in 7 countries. Recruiting first, the newest first:

6 more — sign in →

By country, each count listing its studies:

All 11 open studies →

About nivolumab

Nivolumab: first FDA approval 2014 (OPDIVO), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 435 Squamous Cell Carcinoma of Head and Neck studies recruiting now, 311 (71%) set no upper age limit and 87 (20%) stop at 75 or younger; 5 take children under 18; 13 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 46 studies testing nivolumab in Squamous Cell Carcinoma of Head and Neck, or all of them as a file.
02

Study summary

This study has two, independent, cohorts, both in locally advanced squamous cell head and neck cancer. The purpose of the first cohort is to determine whether nivolumab in combination with radiotherapy is more effective than cetuximab in combination with radiotherapy, in subjects who are ineligible for cisplatin. The purpose of the second cohort is to determine whether nivolumab, cisplatin, and radiotherapy is more effective than cisplatin and radiotherapy in subjects who are eligible to receive cisplatin

03

Conditions studied

  • Squamous Cell Carcinoma of the Head and Neck
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com

Inclusion criteria

Inclusion Criteria:

  • proven squamous cell carcinoma of the head and neck (SCCHN) from one of the following primary sites: oral cavity, oropharynx, hypopharynx, and larynx
  • Locally advanced disease which is unresectable, or resectable but suitable for an organ sparing approach
  • No previous radiotherapy or systemic treatment for SCCHN

Exclusion criteria

Exclusion Criteria:

  • Carcinoma originating in the nasopharynx or paranasal sinus, squamous cell carcinoma that originated from the skin and salivary gland or non-squamous histology (e.g., mucosal melanoma), squamous cell carcinoma of unknown primary
  • Clinical or radiological evidence of disease
  • Prior radiotherapy that overlaps with radiation fields

Other protocol defined inclusion/exclusion criteria could apply

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
74 participants (actual)

Study arms

  • Experimental
    Arm A

    Cohort 1

    Biological: Nivolumab · Radiation: Radiotherapy

  • Experimental
    Arm B

    Cohort 1

    Drug: Cetuximab · Radiation: Radiotherapy

  • Experimental
    Arm C

    Cohort 2

    Biological: Nivolumab · Drug: Cisplatin · Radiation: Radiotherapy

  • Experimental
    Arm D

    Cohort 2

    Drug: Cisplatin · Radiation: Radiotherapy

Interventions

  • BiologicalNivolumab

    Specified dose on specified day

    Also known as: BMS-936558, Opdivo

  • Specified dose on specified day

    Also known as: Erbitux

  • Specified dose on specified day

  • RadiationRadiotherapy

    Specified dose on specified day

06

What researchers measure

Primary outcomes

  1. Number of Participants With an Adverse Event (AE)

    Number of Participants with an Adverse Event

    Time frame: 30 Days

  2. Number of Participants With an Serious Adverse Event (SAE)

    Number of Participants with an Serious Adverse Event (SAE)

    Time frame: 30 days

  3. Number of Participants With an Adverse Event Leading to Discontinuation

    Number of Participants with an Adverse Event Leading to Discontinuation

    Time frame: 30 Days

  4. Number of Participants With an Adverse Event Leading to Dose Modification

    Number of Participants with an Adverse Event Leading to dose modification

    Time frame: 30 Days

  5. Number of Participants With Select Adverse Events

    Number of Participants with select adverse events. Select Adverse events include: gastrointestinal, hepatic, hypersensitivity/infusion reaction, pulmonary, renal, or skin.

    Time frame: 30 Days

  6. Number of Participants With an Immune-mediated Adverse Event (IMAE)

    Number of Participants with an immune-mediated adverse event (IMAE)

    Time frame: 100 days

  7. Time to Onset and Time to Resolution of Immune-related Adverse Events

    Time to onset and time to resolution of immune-related adverse events

    Time frame: 100 days

  8. Number of Participants Who Experienced Death

    Number of Participants who experienced death

    Time frame: 100 days

  9. Number of Participants With an Abnormality in Specific Thyroid Tests

    Number of participants with an abnormality in specific thyroid tests

    Time frame: 30 Days

  10. Number of Participants With an Abnormality in Specific Liver Tests

    Number of participants with an abnormality in specific liver tests

    Time frame: 30 days

07

Results

Posted Aug 9, 2021

Participant flow

Randomized
Participant flow — Randomized
MilestoneArm A (Cohort 1)Arm B (Cohort 1)Arm C (Cohort 2)Arm D (Cohort 2)
Started12102725
Completed12102724
Not completed0001
Treatment Period
Participant flow — Treatment Period
MilestoneArm A (Cohort 1)Arm B (Cohort 1)Arm C (Cohort 2)Arm D (Cohort 2)
Started12102724
Completed0000
Not completed12102724
Withdrew: Death0010
Withdrew: Disease progression0201
Withdrew: Study drug toxicity1011
Withdrew: Adverse event unrelated to study drug2111
Withdrew: Admin reason by sponsor07019
Withdrew: Other reason2021
Withdrew: Completed60181
Withdrew: Participant request to discontinue0040
Withdrew: Participant withdrew consent1000

Outcome measures

PrimaryNumber of Participants With an Adverse Event (AE)

Number of Participants with an Adverse Event

Time frame:
30 Days
Reported as:
Count of participants · Participants
Number of Participants With an Adverse Event (AE)
ParticipantsArm A (Cohort 1)Arm B (Cohort 1)Arm C (Cohort 2)Arm D (Cohort 2)
Number of Participants With an Adverse Event (AE)12102724
PrimaryNumber of Participants With an Serious Adverse Event (SAE)

Number of Participants with an Serious Adverse Event (SAE)

Time frame:
30 days
Reported as:
Count of participants · Participants
Number of Participants With an Serious Adverse Event (SAE)
ParticipantsArm A (Cohort 1)Arm B (Cohort 1)Arm C (Cohort 2)Arm D (Cohort 2)
Number of Participants With an Serious Adverse Event (SAE)5596
PrimaryNumber of Participants With an Adverse Event Leading to Discontinuation

Number of Participants with an Adverse Event Leading to Discontinuation

Time frame:
30 Days
Reported as:
Count of participants · Participants
Number of Participants With an Adverse Event Leading to Discontinuation
ParticipantsArm A (Cohort 1)Arm B (Cohort 1)Arm C (Cohort 2)Arm D (Cohort 2)
Number of Participants With an Adverse Event Leading to Discontinuation2384
PrimaryNumber of Participants With an Adverse Event Leading to Dose Modification

Number of Participants with an Adverse Event Leading to dose modification

Time frame:
30 Days
Reported as:
Count of participants · Participants
Number of Participants With an Adverse Event Leading to Dose Modification
ParticipantsArm A (Cohort 1)Arm B (Cohort 1)Arm C (Cohort 2)Arm D (Cohort 2)
Number of Participants With an Adverse Event Leading to Dose Modification0000
PrimaryNumber of Participants With Select Adverse Events

Number of Participants with select adverse events. Select Adverse events include: gastrointestinal, hepatic, hypersensitivity/infusion reaction, pulmonary, renal, or skin.

Time frame:
30 Days
Reported as:
Count of participants · Participants
Number of Participants With Select Adverse Events
ParticipantsArm A (Cohort 1)Arm B (Cohort 1)Arm C (Cohort 2)Arm D (Cohort 2)
Gastrointestinal4331
Hepatic1223
Hypersensitivity/Infusion Reaction1300
Pulmonary0000
Renal21136
Skin771211
PrimaryNumber of Participants With an Immune-mediated Adverse Event (IMAE)

Number of Participants with an immune-mediated adverse event (IMAE)

Time frame:
100 days
Reported as:
Count of participants · Participants
Number of Participants With an Immune-mediated Adverse Event (IMAE)
ParticipantsArm A (Cohort 1)Arm B (Cohort 1)Arm C (Cohort 2)Arm D (Cohort 2)
Non-Endocrine related IMAE1030
Endocrine related IMAE0040
PrimaryTime to Onset and Time to Resolution of Immune-related Adverse Events

Time to onset and time to resolution of immune-related adverse events

Time frame:
100 days

No measurements were reported for this outcome.

PrimaryNumber of Participants Who Experienced Death

Number of Participants who experienced death

Time frame:
100 days
Reported as:
Count of participants · Participants
Number of Participants Who Experienced Death
ParticipantsArm A (Cohort 1)Arm B (Cohort 1)Arm C (Cohort 2)Arm D (Cohort 2)
Number of Participants Who Experienced Death2221
PrimaryNumber of Participants With an Abnormality in Specific Thyroid Tests

Number of participants with an abnormality in specific thyroid tests

Time frame:
30 Days
Reported as:
Count of participants · Participants
Number of Participants With an Abnormality in Specific Thyroid Tests
ParticipantsArm A (Cohort 1)Arm B (Cohort 1)Arm C (Cohort 2)Arm D (Cohort 2)
TSH > ULN5171
TSH > ULN WITH TSH <= ULN AT BASELINE5171
TSH >ULN WITH ATLEAST ONE FT3/FT4 TEST VALUE <LLN4040
TSH >ULN WITH ALL OTHER FT3/FT4 TEST VALUES >= LLN0021
TSH > ULN WITH FT3/FT4 TEST MISSING1110
TSH < LLN431613
TSH <LLN WITH TSH >= LLN AT BASELINE331313
TSH <LLN WITH ATLEAST ONE FT3/FT4 TEST VALUE > ULN0092
TSH <LLN WITH ALL OTHER FT3/FT4 TEST VALUES <= ULN4167
TSH < LLN WITH FT3/FT4 TEST MISSING0214
PrimaryNumber of Participants With an Abnormality in Specific Liver Tests

Number of participants with an abnormality in specific liver tests

Time frame:
30 days
Reported as:
Count of participants · Participants
Number of Participants With an Abnormality in Specific Liver Tests
ParticipantsArm A (Cohort 1)Arm B (Cohort 1)Arm C (Cohort 2)Arm D (Cohort 2)
ALT OR AST > 3XULN2000
ALT OR AST> 5XULN1000
ALT OR AST> 10XULN0000
ALT OR AST > 20XULN0000
TOTAL BILIRUBIN > 2XULN0000
ALT/AST ELEV>3XULN;TOTAL BILIRUBIN>2XULN IN 1 DAY0000
ALT/AST ELEV>3XULN;TOTAL BILIRUBIN>2XULN IN 30DAYS0000

Adverse events

Collected over 101 days approximately. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Arm A (Cohort 1)2/12 (16.7%)6/12 (50%)12/12 (100%)
Arm B (Cohort 1)2/10 (20%)5/10 (50%)10/10 (100%)
Arm C (Cohort 2)2/27 (7.4%)10/27 (37%)26/27 (96.3%)
Arm D (Cohort 2)1/24 (4.2%)7/24 (29.2%)24/24 (100%)
Most frequent serious events
Showing 10 of 43
Most frequent serious events
EventArm A (Cohort 1)Arm B (Cohort 1)Arm C (Cohort 2)Arm D (Cohort 2)
Cardiac failureCardiac disorders0/121/100/270/24
PneumoniaInfections and infestations0/121/100/270/24
HyperglycaemiaMetabolism and nutrition disorders0/121/100/270/24
Cerebrovascular accidentNervous system disorders0/121/100/270/24
Pharyngeal necrosisRespiratory, thoracic and mediastinal disorders0/121/100/270/24
Myocardial infarctionCardiac disorders1/120/100/270/24
SepsisInfections and infestations1/120/100/270/24
Transaminases increasedInvestigations1/120/100/270/24
Decreased appetiteMetabolism and nutrition disorders0/120/100/272/24
Oropharyngeal squamous cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/120/100/270/24
Most frequent other events
Showing 10 of 140
Most frequent other events
EventArm A (Cohort 1)Arm B (Cohort 1)Arm C (Cohort 2)Arm D (Cohort 2)
NauseaGastrointestinal disorders3/121/1017/2711/24
ConstipationGastrointestinal disorders4/122/1013/2712/24
DysphagiaGastrointestinal disorders6/123/1011/275/24
FatigueGeneral disorders4/125/108/273/24
Radiation skin injuryInjury, poisoning and procedural complications4/125/108/2712/24
AnaemiaBlood and lymphatic system disorders4/123/1012/278/24
Dry mouthGastrointestinal disorders4/123/1012/279/24
DysgeusiaNervous system disorders2/122/1012/276/24
Decreased appetiteMetabolism and nutrition disorders4/122/109/2710/24
Weight decreasedInvestigations3/122/1011/277/24

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Arm A (Cohort 1)Arm B (Cohort 1)Arm C (Cohort 2)Arm D (Cohort 2)Total
Mean74.5 ± 8.374.7 ± 6.559.0 ± 6.660.8 ± 7.064.2 ± 9.7
Sex: Female, Male
Sex: Female, Male(Participants)Arm A (Cohort 1)Arm B (Cohort 1)Arm C (Cohort 2)Arm D (Cohort 2)Total
Female22329
Male108242365
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Arm A (Cohort 1)Arm B (Cohort 1)Arm C (Cohort 2)Arm D (Cohort 2)Total
Hispanic or Latino00000
Not Hispanic or Latino549220
Unknown or Not Reported76182354
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Arm A (Cohort 1)Arm B (Cohort 1)Arm C (Cohort 2)Arm D (Cohort 2)Total
American Indian or Alaska Native00000
Asian3461528
Native Hawaiian or Other Pacific Islander00000
Black or African American00202
White8516736
More than one race00000
Unknown or Not Reported11338
08

Study locations

55 sites
  • Pinnacle Research Group, Llc
    Anniston, Alabama 36207, United States
  • Cancer Treatment Centers of Phoneix
    Goodyear, Arizona 85338, United States
  • University of Arizona Cancer Center
    Tucson, Arizona 85724-5024, United States
  • UCLA Health
    Los Angeles, California 90095, United States
  • Cancer Care - Torrance Memorial Physician Network
    Redondo Beach, California 90277, United States
  • Cancer Center of Central Connecticut
    Plainville, Connecticut 06062, United States
  • Orlando Health, Inc
    Orlando, Florida 32806, United States
  • Winship Cancer Insitute, Emory Crawford Long Hospital
    Atlanta, Georgia 30308, United States
  • CTCA Southeastern Region
    Newnan, Georgia 30265, United States
  • Lewis Hall Singletary Oncology Center at John D. Archbold Memorial Hospital
    Thomasville, Georgia 31792, United States
  • Midwestern Regional medical Center
    Zion, Illinois 60099, United States
  • Fort Wayne Medical Oncology and Hematology, Inc.
    Fort Wayne, Indiana 46845, United States
  • University of Kansas Cancer Center
    Westwood, Kansas 66205, United States
  • Nebraska Methodist Hospital
    Omaha, Nebraska 68114-4108, United States
  • Monter Cancer Center - Center for Advanced Medicine Location
    Lake Success, New York 11042, United States
  • Eastern Regional Medical Center
    Philadelphia, Pennsylvania 19124, United States
  • Upmc- Hillman Cancer Center
    Pittsburgh, Pennsylvania 15232, United States
  • St. Joseph Regional Cancer Center
    Bryan, Texas 77802-2585, United States
  • The University of Texas MD Anderson Cancer Center-merge
    Houston, Texas 77030, United States
  • Inova Health System
    Falls Church, Virginia 22042, United States
  • HHP Hematology & Oncology Bremerton
    Bremerton, Washington 98310, United States
  • Local Institution
    Grenoble, 38043, France
  • Local Institution
    Marseille, 13005, France
  • Local Institution
    Nice, 6100, France
  • Local Institution
    Lucca, 55100, Italy
  • Local Institution
    Ravenna, 48121, Italy
  • Local Institution
    Nagoya, Aichi 4648681, Japan
  • Local Institution
    Kashiwa-shi, Chiba 2778577, Japan
  • Local Institution
    Matsuyama-shi, Ehime 791-0280, Japan
  • Local Institution
    Fukuoka-shi, Fukuoka 8128582, Japan
  • Local Institution
    Akashi-shi, Hyogo 6738558, Japan
  • Local Institution
    Kobe-shi, Hyogo 6500017, Japan
  • Local Institution
    Tsukuba-shi, Ibaraki 3058576, Japan
  • Local Institution
    Isehara, Kanagawa 2591193, Japan
  • Local Institution
    Natori-shi, Miyagi 981-1293, Japan
  • Local Institution
    Osaka-sayama-shi, Osaka 5898511, Japan
  • Local Institution
    Bunkyo-ku, Tokyo 113-8519, Japan
  • Local Institution
    Osaka, 5418567, Japan
  • Local Institution
    Cheongju-si, 28644, Korea, Republic of
  • Local Institution
    Jeollanam-do, 58128, Korea, Republic of
  • Local Institution
    Seoul, 06351, Korea, Republic of
  • Local Institution
    Seoul, 06591, Korea, Republic of
  • Local Institution
    Gdynia, 81 519, Poland
  • Local Institution
    Moscow, 129515, Russian Federation
  • Local Institution
    Yekaterinburg, 620036, Russian Federation
  • Local Institution
    A Coruna, 15706, Spain
  • Local Institution
    Barcelona, 08003, Spain
  • Local Institution
    Madrid, 28046, Spain
  • Local Institution
    Madrid, 28942, Spain
  • Local Institution
    Majadahonda, 28222, Spain
  • Local Institution
    Valencia, 46015, Spain
  • Local Institution
    Taichung, 40447, Taiwan
  • Local Institution
    Taichung, 40705, Taiwan
  • Local Institution
    Tainan, 704, Taiwan
  • Local Institution
    Izmir, 35000, Turkey
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2017 to primary completion in Oct 2019, 21 months.

Results were first posted in Aug 2021, 1 year 9 months after primary completion.

Of 78 phase 3 interventional studies under Squamous Cell Carcinoma of Head and Neck, half reached primary completion within 76 months of starting (the median), counting those still running; a quarter within 38 and three quarters within 117. This study's 21 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 17, 2017
First posted
Nov 21, 2017
StartActual
Dec 15, 2017
Primary completionActual
Oct 14, 2019
CompletionActual
Oct 14, 2019
Results first posted
Aug 9, 2021
Last update
Aug 9, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 9, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03349710
Responsible party
Sponsor
First posted
Nov 21, 2017
Start date
Dec 15, 2017
Primary completion
Oct 14, 2019
Completion
Oct 14, 2019
Results posted
Aug 9, 2021
Last update
Aug 9, 2021

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Nivolumab · Cetuximab · Cisplatin

Start the discussion